{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:25:22Z","timestamp":1785911122258,"version":"3.56.0"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T00:00:00Z","timestamp":1160524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      To report our clinical experience and 5\u2010year prostate\u2010specific antigen (PSA) relapse\u2010free survival rate for early\u2010stage prostate cancer after\n                      <jats:sup>125<\/jats:sup>\n                      I low\u2010dose\u2010rate prostate brachytherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>In all, 300 patients were treated between March 1999 and April 2003, and followed prospectively. Patients were stratified into low\u2010, intermediate\u2010 and high\u2010risk groups, and those receiving neoadjuvant androgen deprivation (NAAD) or not. Kaplan\u2013Meier estimates of PSA relapse\u2010free survival and PSA nadirs were obtained for all patients and for the risk groups. Toxicity, as urinary and erectile dysfunction (ED), were reported from a prospective database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The median (range) follow\u2010up was 45\u2003 (33\u201382)\u2003months. The actuarial PSA relapse\u2010free survival was 93% at 5\u2003years; 21 (7%) of patients had evidence of biochemical failure as defined by the American Society of Therapeutic Radiation Oncology criteria. There was no significant difference in actuarial survival for patients in the different risk groups, or between those receiving NAAD or not (low\u2010risk 96%, intermediate 89%, high 93%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.12; NAAD 92%, no NAAD 95%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.30). Overall the 3\u2010year median PSA level was 0.3\u2003ng\/mL (192 men). There was no significant difference in median 3\u2010year PSA levels for different risk groups, or for those treated with or with no NAAD. The 3\u2010 and 4\u2010year PSA nadir of &lt;0.5\u2003ng\/mL was achieved by 71% and 86% of men, respectively. The acute urinary retention rate was 7%; 5.6% of men developed urethral strictures requiring dilatation, while 2.7% required a transurethral resection of the prostate after implantation, for obstructive symptoms. Of patients with no ED before treatment, 62% had no ED at 2\u2003years, and of these 60% used a phosphodiesterase inhibitor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      This prospective series confirms the excellent overall biochemical survival after\n                      <jats:sup>125<\/jats:sup>\n                      I brachytherapy; the treatment was tolerated well, with early and late urinary toxicity and ED similar to other published results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06520.x","type":"journal-article","created":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T23:57:59Z","timestamp":1160611079000},"page":"1210-1215","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Biochemical (prostate\u2010specific antigen) relapse\u2010free survival and toxicity after\n                    <sup>125<\/sup>\n                    I low\u2010dose\u2010rate prostate brachytherapy"],"prefix":"10.1111","volume":"98","author":[{"given":"Sara Jane","family":"Khaksar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna","family":"Sooriakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.M.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01601-7"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00499-X"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01594-2"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<989::AID-CNCR26>3.0.CO;2-Q"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00123-5"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00091-1"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-4096.2001.01610.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900857"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80138-7"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900472"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02675-X"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.10.001"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901271"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.12.008"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2005.00081_1.x"},{"key":"e_1_2_7_17_2","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel","volume":"37","author":"ASTRO.","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000152556.53602.64"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00006-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00791-3"},{"key":"e_1_2_7_21_2","first-page":"375","article-title":"Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate cancer","volume":"7","author":"D\u2019Amico AV","year":"2001","journal-title":"Cancer J"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.164"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02658-X"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00666-8"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00069-3"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(96)00214-3"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(00)00100-9"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00784-7"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2002.02983.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01811-9"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06520.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06520.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:54:08Z","timestamp":1761735248000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06520.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,7]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06520.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06520.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,7]]},"assertion":[{"value":"2006-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}